Geographic Variations in the Prevalence, Awareness, Treatment, and Control of Dyslipidemia among Chinese Adults in 2018-2019: A Cross-sectional Study.

Mei Zhang; Ke Peng; Xiao Zhang; Yi Shu Liu; Xiao Ying Liu; Gui Yuan Han; Yu Shi; Zheng Jing Huang; Chun LI; Zhen Ping Zhao; Li Min Wang; Yi Chong LI

Return

Geographic Variations in the Prevalence, Awareness, Treatment, and Control of Dyslipidemia among Chinese Adults in 2018-2019: A Cross-sectional Study.

Author: Mei ZHANG ¹ ; Ke PENG ² ; Xiao ZHANG ¹ ; Yi Shu LIU ^{3
,

4} ; Xiao Ying LIU ^{3
,

5} ; Gui Yuan HAN ² ; Yu SHI ² ; Zheng Jing HUANG ¹ ; Chun LI ¹ ; Zhen Ping ZHAO ¹ ; Li Min WANG ¹ ; Yi Chong LI ²
Author Information

1. National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
2. National Clinical Research Center for Cardiovascular Diseases, Shenzhen, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518057, Guangdong, China.
3. National Clinical Research Center for Cardiovascular Diseases, Shenzhen, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen 518057, Guangdong, China
4. The George Institute for Global Health, 2042, New South Wales, Australia.
5. School of Medical Science, Faculty of Medicine and Health, University of Sydney, 2006, New South Wales, Australia.
Publication Type:Journal Article
Keywords: Chinese; Dyslipidemia; Lipids management; Public health
MeSH: Humans; Adult; Middle Aged; Aged; Cross-Sectional Studies; Prevalence; East Asian People; Dyslipidemias/prevention & control*; China/epidemiology*; Cholesterol, HDL; Risk Factors; Triglycerides
From: Biomedical and Environmental Sciences 2023;36(4):313-323
CountryChina
Language:English
Abstract: OBJECTIVE:To investigate the spatial patterns of the prevalence, awareness, treatment, and control rates of dyslipidemia at the provincial level in China.
METHODS:A national and provincial representative cross-sectional survey was conducted among 178,558 Chinese adults in 31 provinces in mainland China in 2018-2019, using a multi-stage, stratified, cluster-randomized sampling design. Subjects, as households, were selected, followed by a home visit to collect information. Both descriptive and linear regression procedures were applied in the analyses.
RESULTS:The overall prevalence of dyslipidemia was 35.6%, and wide geographic variations of prevalence, treatment, and control rates of dyslipidemia were identified among 178,558 eligible participants with a mean age of 55.1 ± 13.8 years. The highest-lowest difference regarding the provincial level prevalence rates were 19.7% vs. 2.1% for high low-density lipoprotein cholesterol, 16.7% vs. 2.5% for high total cholesterol, 35.9% vs. 5.4% for high triglycerides, and 31.4% vs. 10.5% for low high-density lipoprotein cholesterol. The treatment rate of dyslipidemia was correlated with the socio-demographic index ( P < 0.001), urbanization rate ( P = 0.01), and affordable basic technologies and essential medicines ( P < 0.001).
CONCLUSION:Prevailing dyslipidemia among the Chinese population and its wide geographic variations in prevalence, treatment, and control suggest that China needs both integrated and localized public health strategies across provinces to improve lipid management.